Login | Register
Profile | Log out
logo

  • Home
  • News
  • Opinion
  • Other
    • Market Updates
    • Explainers
    • Satire
  • About
  • Contact Us
    • Contact
    • Get Covered
    • Posting Guidelines
  • Subscribe
Submit An Article

Blog

  • Home
  •  
  • Blog



  • Most Read
  • Latest Comments
  • Blog
    • News

    RBA and ASIC up the ante on blockchain project, ASX writes off millions
    Public
  • Blog
    • Satire

    Australia to close borders to Omicron Persei 8
    Public
  • Blog
    • Opinion

    The New Criterion: will the listed sanitiser stocks clean up – or clean out – investors?
    Public
  • Blog
    • Opinion

    Is this the most hated company on the ASX?
    Public
  • Blog
    Opening a new frontier in treating Parkinson’s disease
    • Review
    • November 11, 2022
  • Tremors from the FTX collapse continue to be felt as DigitalX sells off 15% Bitcoin holdings
    • Review
    • January 10, 2023
  • AUDC stablecoin gathers momentum as Novatti confirms integration with XRP Ledger
    • Review
    • June 9, 2022
  • PharmAust completes dosing first cohort for MND treatment, patients respond positively
    • Review
    • January 6, 2023
  • Is this the most hated company on the ASX?
    • Review
    • August 16, 2019

Latest Articles

  • AML3D announces stronger FY26, with positive EBITDA reported in the second half
    AML3D announces stronger FY26, with positive EBITDA reported in the second half
    • News

  • Refurbished tech gives Harris Technology a second life
    Refurbished tech gives Harris Technology a second life
    • News

  • Imagion Biosystems Advances MagSense® Phase 2 Trial
    Imagion Biosystems Advances MagSense® Phase 2 Trial
    • News

  • Acrux-developed Menopause Hormone Therapy to enter Australian market
    Acrux-developed Menopause Hormone Therapy to enter Australian market
    • News

  • Evion Expands Critical Minerals Push with Nevada Fluorspar Option
    Evion Expands Critical Minerals Push with Nevada Fluorspar Option
    • News

  • A unicorn brewing? Institutions back Novatti with $40m investment
    • News

    A unicorn brewing? Institutions back Novatti with $40m investment

    Since offering their last capital raise to accelerate growth, digital payments company Novatti Group (ASX: NOV) has increased its market cap by more than 200% which was one reason institutions were keen to get involved with the Aussie fintech and their latest expansion plans.  The cornerstone of what will be a total $45 million raise

    Read More
    Public
  • Curing sickness with viruses: How Imugene is using oncolytic viruses to treat cancer
    • News

    Curing sickness with viruses: How Imugene is using oncolytic viruses to treat cancer

    Despite the many advances in cancer therapy, we still haven’t quite hit the nail on the head, with cancer still responsible for 12% of all deaths worldwide each year.  The advancement of cancer therapies and the growing body of research is impressive to say the least, yet cancer patients of today do not fare much

    Read More
    Public
  • IPO Watch: Lumos to accelerate decentralised healthcare diagnostics with $187m float
    • News

    IPO Watch: Lumos to accelerate decentralised healthcare diagnostics with $187m float

    With ever increasing bodies of medical research and demand for early disease detection climbing, it’s high time that we rethink diagnostic testing. The trend of having to wait three days to see if your pee is free of nasties is fraught with administration challenges and can delay treatment. Spend time in any medical establishment and

    Read More
    Public
  • Four’n Twenty re-brands as ‘Humble’ in New South Wales
    • Satire

    Four’n Twenty re-brands as ‘Humble’ in New South Wales

    With more than 200,000 pies that have been left unsold due to New South Wales entering COVID lockdown where the AFL and NRL have fled the State, pie manufacturer Four’n Twenty has come up with a novel way to offload their huge stockpile of pies.  Until further notice, all Four’n Twenty products in New South

    Read More
    Public
  • Pharmaxis streamlines operations with $2m sale of Australian distribution rights
    • News

    Pharmaxis streamlines operations with $2m sale of Australian distribution rights

    Having successfully developed a number of drugs through to regulatory approval and commercial sales, Pharmaxis (ASX: PXS) is set to realise a $2 million windfall with the sale of their Australian distribution rights, a move that will focus the Company’s efforts towards their advancing cancer treatment clinical trials. The deal will send the distribution rights

    Read More
    Public
  • Truscreen expands market for real time digital diagnostic testing device
    • News

    Truscreen expands market for real time digital diagnostic testing device

    Ahh the pap smear. The daunting, uncomfortable and downright annoying process of having a cervical swab taken to be tested for cancerous or precancerous cells, only to be repeated in 3-5 years time.  Despite being an important aspect of women’s health – COVID-19, uncomfortable gyno appointments, and misinformation means that booking in for that test

    Read More
    Public
  • «
  • ‹
  • 486
  • 487
  • 488
  • 489
  • 490
  • ›
  • »

Login or register for free to access unlimited reading

Register Now!
  • News

  • Opinion

  • Satire

  • About

  • Contact Us

  • Subscribe

The content published on this website is solely for general information purposes and is not to be construed as financial advice. Should you seek financial advice you should consult with an appropriately qualified person. Opinions expressed on this site are subject to change without notice and The Sentiment who produced this content is under no obligation to keep the information current. The Sentiment, affiliated companies & associates may have a conflict of interest with companies discussed on the website due to commercial arrangements, for example they may be shareholders in the company, be engaged by them to assist in investor communications or receive commission/brokerage for funds raised.

Copyright © 2020 The Sentiment. All rights reserved.
Subscribe

Enter your email address below to subscribe to The Sentiment’s weekly newsletter, highlighting the top news, research, opinion and satire articles shaping ASX investor sentiment.

The Sentiment respects your privacy and will not spam you. View our privacy policy here.